文献速递免疫规划传染病防控与疫情报告

加拿大CHILD队列:儿童与成人接种两剂COVID-19疫苗后抗Spike IgG抗体水平的预测因素

Predictors of SARS-CoV-2 anti-Spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort.
PubMed 文献 · Vaccine · 2026-03-19

研究基于加拿大CHILD队列中151名儿童和995名成人,分析接种两剂COVID-19疫苗后抗SARS-CoV-2 Spike IgG抗体水平及相关因素。结果显示双剂接种后血清阳性率达97%,抗体水平在接种后约三个月最高,既往感染、年龄<18岁和接种mRNA疫苗与更高抗体水平相关。

要点

  • 双剂接种后抗Spike血清阳性率为97%,抗体水平约在接种后3个月最高。
  • 既往SARS-CoV-2感染、年龄<18岁及接种mRNA疫苗与更高抗体水平独立相关。
  • 不同研究站点、 ethnicity、家庭必要工作者身份、教育水平、免疫抑制合并症及接种间隔未见抗体水平差异。

核心结论

  • 儿童和成人接种两剂COVID-19疫苗后,既往SARS-CoV-2感染、年龄<18岁和接种mRNA疫苗与更高的抗Spike IgG抗体水平相关。

研究设计与样本

  • 研究为加拿大跨省CHILD队列中部分双剂接种儿童(n=151,平均年龄12±1.5岁,46%女性)和成人(n=995,44±6.0岁,60%女性)的观察性分析。
  • 干血斑在2021年3月至2021年9月及2021年10月至2022年1月两个时间段采集,抗体用自动化化学发光ELISA定量。
  • 通过在线问卷收集人口学、疫苗接种和健康数据,采用多变量线性混合效应模型分析并考虑家庭内聚集。

主要发现

  • 队列双剂接种后SARS-CoV-2抗Spike血清阳性率为97%。
  • 儿童和成人中抗体水平均在接种后约三个月最高,且不因生理性别而异。
  • 既往SARS-CoV-2感染与更高抗体水平相关(β=0.16缩放发光单位;95%CI 0.07,0.25)。
  • 年龄<18岁与更高抗体水平相关:13-17岁β=0.14(95%CI 0.03,0.25),<13岁β=0.17(95%CI 0.03,0.32)。
  • 接种mRNA疫苗与更高抗体水平相关:两剂Moderna β=0.21(95%CI 0.10,0.33),两剂Pfizer-BioNTech β=0.10(95%CI 0.02,0.18),混合接种β=0.14(95%CI 0.01,0.27),均对比Oxford-AstraZeneca病毒载体疫苗。

临床怎么用

  • 在评估个体接种后体液免疫水平时,可考虑既往感染史、年龄和疫苗类型等与抗体水平相关的因素。
  • 研究结果提示mRNA疫苗相比病毒载体疫苗与更高抗体水平相关,可供未来疫苗选择和部署参考。
  • 抗体水平在接种后约三个月最高,提示监测或加强策略需考虑时间因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination helps prevent SARS-CoV-2 infection and severe COVID-19. However, vaccine-induced humoral immune responses vary among individuals and wane over time. We aimed to describe the SARS-CoV-2 anti-spike IgG antibody response to vaccination and identify health and demographic factors associated with this response among children and adults. METHODS: We studied a subset of double-vaccinated children (n = 151; mean age: 12 ± 1.5 years, 46% female) and adults (n = 995; 44 ± 6.0 years, 60% female) from the cross-provincial Canadian CHILD Cohort. Dried blood spots were collected over two time periods (March 2021 to September 2021; October 2021 to January 2022). Antibody levels were quantified using automated chemiluminescent ELISAs. Demographic, vaccination, and health data (e.g. location, age, ethnicity, prior SARS-CoV-2 infection, vaccine type, comorbidities) were collected via online questionnaires. Associations were tested using multivariable linear mixed-effect analysis accounting for household membership. RESULTS: Our cohort had SARS-CoV-2 anti-spike seropositivity rate of 97% following two COVID-19 vaccine doses. In both children and adults, the highest antibody levels were observed around three months post-vaccination and did not differ by biological sex. Higher antibody levels were associated with: prior SARS-CoV-2 infection (β = 0.16 scaled luminescence units; 95%CI 0.07,0.25), age < 18 years (13-17 years old, β = 0.14; 95%CI 0.03,0.25 | <13 years old: β = 0.17; 95%CI 0.03,0.32) and receiving mRNA vaccines (two Moderna: β = 0.21; 95%CI 0.10,0.33 | two Pfizer-BioNTech (β = 0.10; 95%CI 0.02,0.18 | one Modern and one Pfizer-BioNTech β = 0.14; 95%CI 0.01,0.27) vs. receiving Oxford-AstraZeneca viral vector vaccines. There were no antibody level differences among study sites, ethnicities, household essential worker status, education levels, immunosuppressive comorbidity presence, or when comparing a 3-8 vs. 9-16-week interval between vaccine doses. INTERPRETATION: We identified key factors (i.e. prior SARS-CoV-2 infection, age, vaccine type) associated with post-vaccination antibody responses in children and adults across Canada. This may help improve future vaccine development and deployment among different population subgroups.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Azeez R, Ames SR, Lotoski LC, et al. Predictors of SARS-CoV-2 anti-Spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort. Vaccine. 2026. PMID: 41863181. doi:10.1016/j.vaccine.2026.128342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。